Literature DB >> 24674846

Acute but not sustained aromatase inhibition displays antidepressant properties.

Nikolaos Kokras1, Nikolaos Pastromas1, Tatiany H Porto1, Vasilios Kafetzopoulos1, Theodore Mavridis1, Christina Dalla1.   

Abstract

Aromatase inhibitors block the conversion of androgens to oestrogens and are used for the treatment of hormone-responsive breast cancer in menopause and recently also in premenopausal women. We investigate whether decreased oestrogen synthesis following aromatase inhibition leads to a depressive-like behavioural response in cycling female rats. Using the forced swim test (FST) we estimate the response of acute (three injections in 24 h) and sustained (7 d) letrozole and fluoxetine administration. Acute aromatase inhibition decreases immobility duration in the FST, indicating its antidepressant potential. Instead, sustained aromatase inhibition did not show such antidepressant potential. Testosterone elevation associates with the decreased depressive behaviour in the FST following acute letrozole treatment, but interestingly progesterone explains the increased swimming behaviour. Present findings may have potential implications for women treated with aromatase inhibitors, especially before menopause, as well as for the role of gonadal hormones in the expression of depressive symptoms and antidepressant response.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24674846     DOI: 10.1017/S1461145714000212

Source DB:  PubMed          Journal:  Int J Neuropsychopharmacol        ISSN: 1461-1457            Impact factor:   5.176


  2 in total

1.  Acute inhibition of neurosteroid estrogen synthesis suppresses status epilepticus in an animal model.

Authors:  Satoru M Sato; Catherine S Woolley
Journal:  Elife       Date:  2016-04-15       Impact factor: 8.140

2.  Kinoscope: An Open-Source Computer Program for Behavioral Pharmacologists.

Authors:  Nikolaos Kokras; Dimitrios Baltas; Foivos Theocharis; Christina Dalla
Journal:  Front Behav Neurosci       Date:  2017-05-12       Impact factor: 3.558

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.